1-May-2026
InspireMD Recalls CGuard Prime Delivery System, Pauses U.S. Launch
TipRanks (Fri, 1-May 4:45 PM ET)
Globe Newswire (Fri, 1-May 4:05 PM ET)
InspireMD Initiates Voluntary U.S. Recall of CGuard Prime 135 cm Carotid Stent Delivery System
Globe Newswire (Fri, 1-May 4:05 PM ET)
InspireMD Q1 2026 Earnings Preview
Seeking Alpha News (Fri, 1-May 11:54 AM ET)
InspireMD to Announce First Quarter 2026 Financial Results
Globe Newswire (Mon, 27-Apr 4:05 PM ET)
PRNewswire (Tue, 14-Apr 9:20 AM ET)
InspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare Conference
Globe Newswire (Tue, 31-Mar 4:05 PM ET)
InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results
Globe Newswire (Wed, 18-Mar 7:00 AM ET)
InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results
Globe Newswire (Mon, 9-Mar 9:00 AM ET)
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
Inspiremd trades on the NASDAQ stock market under the symbol NSPR.
As of May 1, 2026, NSPR stock price declined to $1.15 with 40,867 million shares trading.
NSPR has a beta of -0.24, meaning it tends to be less sensitive to market movements. NSPR has a correlation of 0.01 to the broad based SPY ETF.
NSPR has a market cap of $53.82 million. This is considered a Micro Cap stock.
Last quarter Inspiremd reported $3 million in Revenue and -$.14 earnings per share. This beat revenue expectation by $476,998 and exceeded earnings estimates by $.06.
In the last 3 years, NSPR traded as high as $3.85 and as low as $1.12.
The top ETF exchange traded funds that NSPR belongs to (by Net Assets): IWC.
NSPR has underperformed the market in the last year with a price return of -55.8% while the SPY ETF gained +30.4%. NSPR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -27.2% and -14.8%, respectively, while the SPY returned +4.4% and +1.5%, respectively.
NSPR support price is $1.10 and resistance is $1.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NSPR shares will trade within this expected range on the day.